PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET
Company Participants
Frank Bedu-Addo - Chief Executive Officer
Lauren Wood - Chief Medical Officer
Matthew Hill - Chief Financial Officer
Gabby DeGravina - Investor Relations
Conference Call Participants
Joe Pantginis - HC Wainwright
Lucas Duffy - Cantor Fitzgerald
Kalpit Patel - B. Riley
Leland Gershell - Oppenheimer
Robert LaBoyer - Noble Capital
Laura Suriel - Alliance Global Partners
Operator
Hello and welcome to the PDS Biotechnology Second Quarter 2023 Earnings Call and Webcast.
If anyone should require Operator assistance, please press star, zero on your telephone keypad. A question and answer session will follow the formal presentation. You may press star, one at any time to be placed into question queue. As a reminder, this conference is being recorded.
It is now my pleasure to turn the call over to your host, Gabby DeGravina, Investor Relations. Please go ahead, Gabby.
Gabby DeGravina
Good morning and welcome to PDS Biotechnology’s second quarter 2023 earnings conference call and audio webcast. On the call from the company are Dr. Frank Bedu-Addo, Chief Executive Officer; Matt Hill, Chief Financial Officer, and Dr. Lauren V. Wood, Chief Medical Officer.
Earlier this morning, PDS Biotech issued a press release announcing financial results for the quarter ended June 30, 2023. We encourage everyone to read the press release as well as PDS Biotech’s report on Form 10-Q, which will be filed with the SEC shortly. The company’s press release is available on the PDS website at pdsbiotech.com. In addition, this conference call is being webcast and will be archived on the company website for future reference.
Before we begin, we need to remind everyone that on today’s call, the company will be making forward-looking statements regarding regulatory and clinical candidate development plans, as well as research activities. Certain information in this presentation may include forward-looking statements, including within the meaning of Section 21(e) of the United States Securities Exchange Act of 1934, as amended, and Section 27(a) of the United States Securities Act of 1933, as amended, concerning PDS Biotechnology Corporation and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise based on the current beliefs of the company’s management, as well as assumptions made by and information currently available to management.
These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in PDS Biotech’s most recent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this conference call. Except to the extent required by applicable law or regulation, PDSB undertakes no obligation to update the forward-looking statements included today to reflect subsequent events or circumstances.